STOCK TITAN
  1. Home
  2. News
  3. TLSI

TriSalus Life Sciences Inc. - TLSI STOCK NEWS

Welcome to our dedicated page for TriSalus Life Sciences news (Ticker: TLSI), a resource for investors and traders seeking the latest updates and insights on TriSalus Life Sciences stock.

TriSalus Life Sciences, Inc. (symbol: TLSI) is engaged in the research, development, and sale of groundbreaking drug delivery technology and immuno-oncology therapeutics. The company's mission is to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers.

Core Business: TriSalus focuses on two main product lines: the Pressure Enabled Drug Delivery (PEDD) infusion systems and an investigational agent called SD-101 (nelitolimod). The PEDD infusion systems are already in use and are designed to enhance the delivery of therapeutic agents to tumors. The investigational agent SD-101 aims to stimulate the immune system to better combat hepatocellular cancer, pancreatic cancer, and other solid tumors located in the liver.

Recent Achievements: One of the company's major advancements is the development of TriNav, a new therapy delivery device that incorporates SmartValve technology to optimize the PEDD approach. This innovative device has the potential to significantly improve treatment efficacy and patient outcomes.

Current Projects: TriSalus is actively involved in clinical trials to evaluate the effectiveness of SD-101 in various types of liver and pancreatic cancers. These trials are crucial for securing future regulatory approvals and bringing new treatments to market.

Financial Condition: While detailed financial information is not provided, the company's ongoing research and development initiatives, coupled with its active market presence, indicate a robust commitment to transforming cancer treatment.

Partnerships: TriSalus collaborates with leading academic and medical institutions to advance its research and bring innovative therapies to patients. These partnerships are essential for the clinical validation and widespread adoption of its technologies.

Products:

  • PEDD Infusion Systems: These systems enhance drug delivery to tumors, increasing the efficacy of cancer treatments.
  • SD-101 (nelitolimod): An investigational agent designed to boost the immune system's response to liver and pancreatic cancers.
  • TriNav: The latest innovation in therapy delivery devices, featuring SmartValve technology to improve drug delivery efficiency.
News

TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives

Rhea-AI Summary

TriSalus Life Sciences has secured up to $50 million in debt financing with OrbiMed to support the growth of its TriNav® Infusion System. $25 million was funded initially, with an option for an additional $25 million based on revenue thresholds. The financing is expected to fuel strategic expansion, extending the cash runway through 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

Rhea-AI Summary
TriSalus Life Sciences Inc. (TLSI) reported strong financial results for Q4 2023 with revenues of $5.7 million, up 77% YoY, and full-year revenues of $18.5 million, up 49% YoY. The company achieved a gross margin of 90% in Q4 2023 and 86% for the full year. TriSalus received CMS reimbursement for its TriNav Infusion System and published real-world data showing improved therapeutic delivery to liver tumors. They obtained 510k clearance for TriNav Large and TriGuide systems, completed phase 1 trials for liver indications, and initiated a phase 1 trial for a novel pancreatic infusion technology. The company also reported operating losses of $14.1 million in Q4 and $54.2 million for the full year, with net losses of $35.5 million in Q4 and $59.0 million for the full year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.13%
Tags
earnings
-
News

TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

Rhea-AI Summary
TriSalus Life Sciences Inc. (TLSI) presents new safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer and a retrospective clinical study supporting the TriNav Infusion System. The technology integrates novel delivery methods with immunotherapy for liver and pancreatic tumors, featured at the Society of Interventional Radiology Annual Scientific Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting

Rhea-AI Summary
TriSalus Life Sciences Inc. (TLSI) will present data at the 2024 Society of Interventional Radiology Annual Scientific Meeting on their Pressure-Enabled Drug Delivery technology for liver and pancreatic tumors. The company aims to address challenges in delivering therapeutics to pancreas tumors by modulating pressure and flow. TLSI is committed to transforming therapeutic delivery into challenging tumors and improving outcomes in solid tumor indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.95%
Tags
none
-
News

TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results

Rhea-AI Summary
TriSalus Life Sciences Inc. (TLSI) reports strong Q4 sales of approximately $5.7 million, representing 77% growth compared to 2022. Gross margins for Q4 and full year 2023 stand at around 90% and 86% respectively. Full year 2024 sales growth is expected to exceed 50%. The company anticipates having sufficient liquidity to fund operations into the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
earnings
-
News

TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101

Rhea-AI Summary
TriSalus Life Sciences® Inc. announced the approval of the nonproprietary name 'nelitolimod' for its therapeutic candidate SD-101 by WHO and USAN. Nelitolimod is being studied in Phase 1/1b trials for liver and pancreatic cancers. The approval marks a significant milestone for TriSalus in its mission to improve cancer treatment outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
none
News

TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors

Rhea-AI Summary
TriSalus Life Sciences Inc. announces the publication of a study in Current Medical Research and Opinion showcasing the effectiveness of the TriNav Infusion System in treating patients with liver and pancreatic tumors. The study demonstrates TriNav's success in treating sicker patients with higher disease burden, validating previous data in a real-world setting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
News

TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
TriSalus Life Sciences Inc. (Nasdaq: TLSI) completed a merger with MedTech Acquisition Corporation (MTAC) and started public trading on August 11th. The company reported 3Q23 revenues of $5.2 million, up 32% over the prior year, and nine-month net revenues of $12.8 million, up 39% over the prior year. Favorable Phase 1 uveal melanoma PERIO-01 data demonstrated median progression free survival (PFS) of 11.7 months, with an 81% Disease Control Rate and 1 year overall survival (OS) of 86%. Additionally, favorable Phase 1 pancreatic adenocarcinoma PERIO-03 data utilizing an innovative FDA cleared pancreatic delivery device demonstrated initial safety, feasibility, and immunologic response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
earnings
-
News

TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call

Rhea-AI Summary
TLSI to Host Q3 Financial Results Conference Call and Webcast on November 14, 2023, at 9:00 a.m. ET
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
conferences earnings
News

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

Rhea-AI Summary
TriSalus Life Sciences presented additional Phase 1 clinical data at the SITC 2023 Annual Meeting. The data showed that SD-101, delivered via PEDD with the TriNav Infusion System, is well tolerated and associated with immunologic effects within the liver and systemically. The median Progression-Free Survival was 11.7 months with an 81% Disease Control Rate at the optimal biologic dose of SD-101 (2 mg) in combination with nivolumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial

FAQ

What is the current stock price of TriSalus Life Sciences (TLSI)?

The current stock price of TriSalus Life Sciences (TLSI) is $5.76 as of February 28, 2025.

What is the market cap of TriSalus Life Sciences (TLSI)?

The market cap of TriSalus Life Sciences (TLSI) is approximately 172.9M.

What does TriSalus Life Sciences, Inc. do?

TriSalus Life Sciences focuses on developing drug delivery technology and immuno-oncology therapeutics to improve outcomes for liver and pancreatic cancer patients.

What are the main products of TriSalus Life Sciences?

The main products include the Pressure Enabled Drug Delivery (PEDD) infusion systems and an investigational agent called SD-101 (nelitolimod).

What is TriNav?

TriNav is a new therapy delivery device with SmartValve technology, designed to optimize the Pressure Enabled Drug Delivery (PEDD) approach.

What types of cancer does TriSalus target?

TriSalus targets difficult-to-treat liver and pancreatic cancers.

What is the purpose of SD-101 (nelitolimod)?

SD-101 is an investigational agent aimed at boosting the immune system's response to combat hepatocellular cancer, pancreatic cancer, and other liver solid tumors.

Is TriSalus involved in any clinical trials?

Yes, TriSalus is actively conducting clinical trials to evaluate the effectiveness of SD-101 in treating liver and pancreatic cancers.

Who are TriSalus' partners?

TriSalus collaborates with leading academic and medical institutions to advance its research and develop new therapies.

How can I stay updated on TriSalus' latest news?

You can stay updated by following their latest news on financial websites like StockTitan, or the company's official website and press releases.

What is the significance of the PEDD infusion systems?

The PEDD infusion systems enhance the delivery of therapeutic agents to tumors, potentially improving the efficacy of cancer treatments.

Where can I find more information about TriSalus stock?

For the latest updates and relevant information about TriSalus' stock performance, visit financial websites like StockTitan or consult stock market resources.
Stock TLSI logo
TriSalus Life Sciences Inc.

Nasdaq:TLSI

TLSI Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

TLSI Stock Data

172.90M
13.67M
43.32%
17.27%
0.19%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
WESTMINSTER